TY - JOUR
T1 - The use of transvaginal ultrasound in Type II endometrial cancer
AU - Billingsley, Caroline C.
AU - Kenne, Kimberly A.
AU - Cansino, Catherine D
AU - Backes, Floor J.
AU - Cohn, David E.
AU - O'Malley, David M.
AU - Copeland, Larry J.
AU - Fowler, Jeffrey M.
AU - Salani, Ritu
PY - 2015/6/4
Y1 - 2015/6/4
N2 - Objective To determine the use of the transvaginal ultrasound (TVUS) in postmenopausal women with type II endometrial cancer. Methods/Materials A retrospective review was conducted for 173 women with pathology proven type II endometrial cancer at a single institution. Those who underwent preoperative TVUS were included, and the following data were obtained: endometrial stripe (EMS) measurement, uterine and/or adnexal findings, and uterine size/volume. Clinicopathologic factors were abstracted. Descriptive and regression analyses were performed. Results Fifty-eight women comprised the cohort, and the median age was 66.5 years (50-85 years). The most commonly reported symptom was postmenopausal bleeding in 53 patients (91.4%). The EMS was reported as thin (≤5mm) or indistinct in 16 patients (27.5%). Approximately 60% of patients had 1 or more ultrasound abnormalities: intracavitary mass (31%), intracavitary fluid (12.1%), myometrial lesion (31.03%), and adnexal mass (12.1%). Poorly differentiated endometrioid cancer (53.45%) represented the predominant histology. Of the 16 (27.5%) women with a thin/indistinct EMS, 5 women (8.6%) did not have any abnormal ultrasound findings whatsoever. Conclusions Women with type II endometrial cancer had a thin/indistinct EMS on TVUS in approximately 25% of cases. Lack of any ultrasound abnormality, including a thickened EMS, was noted in approximately 10% of patients. The use of TVUS, which has been of value in type I cancer, is limited in type II endometrial cancer. Therefore, endometrial sampling should be included in the evaluation of all women with postmenopausal bleeding, regardless of EMS thickness.
AB - Objective To determine the use of the transvaginal ultrasound (TVUS) in postmenopausal women with type II endometrial cancer. Methods/Materials A retrospective review was conducted for 173 women with pathology proven type II endometrial cancer at a single institution. Those who underwent preoperative TVUS were included, and the following data were obtained: endometrial stripe (EMS) measurement, uterine and/or adnexal findings, and uterine size/volume. Clinicopathologic factors were abstracted. Descriptive and regression analyses were performed. Results Fifty-eight women comprised the cohort, and the median age was 66.5 years (50-85 years). The most commonly reported symptom was postmenopausal bleeding in 53 patients (91.4%). The EMS was reported as thin (≤5mm) or indistinct in 16 patients (27.5%). Approximately 60% of patients had 1 or more ultrasound abnormalities: intracavitary mass (31%), intracavitary fluid (12.1%), myometrial lesion (31.03%), and adnexal mass (12.1%). Poorly differentiated endometrioid cancer (53.45%) represented the predominant histology. Of the 16 (27.5%) women with a thin/indistinct EMS, 5 women (8.6%) did not have any abnormal ultrasound findings whatsoever. Conclusions Women with type II endometrial cancer had a thin/indistinct EMS on TVUS in approximately 25% of cases. Lack of any ultrasound abnormality, including a thickened EMS, was noted in approximately 10% of patients. The use of TVUS, which has been of value in type I cancer, is limited in type II endometrial cancer. Therefore, endometrial sampling should be included in the evaluation of all women with postmenopausal bleeding, regardless of EMS thickness.
KW - Endometrial cancer
KW - Endometrial stripe
KW - Type II, Pelvic ultrasound
UR - http://www.scopus.com/inward/record.url?scp=84930359352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930359352&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000423
DO - 10.1097/IGC.0000000000000423
M3 - Article
C2 - 25768078
AN - SCOPUS:84930359352
VL - 25
SP - 858
EP - 862
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 5
ER -